What is the Pregnancy‑Unique Quantification of Emesis (PUQE‑24) score, how is it calculated, and how should the severity be managed?

PUQE Score: Definition, Calculation, and Management

The PUQE-24 (Pregnancy-Unique Quantification of Emesis) score is a validated 3-question tool that quantifies nausea and vomiting severity in pregnancy over the past 24 hours, with scores of ≤6 indicating mild disease, 7-12 moderate, and 13-15 severe disease, guiding stepwise pharmacologic management. 1

How to Calculate the PUQE-24 Score

The score is calculated by summing responses to three questions, each scored 1-5 points 1:

Question 1: Duration of nausea in last 24 hours

• Not at all = 1 point
• 1 hour or less = 2 points
• 2-3 hours = 3 points
• 4-6 hours = 4 points
• More than 6 hours = 5 points

Question 2: Number of vomiting episodes in last 24 hours

• Did not throw up = 1 point
• 1-2 times = 2 points
• 3-4 times = 3 points
• 5-6 times = 4 points
• 7 or more times = 5 points

Question 3: Number of retching/dry heaves in last 24 hours

• No times = 1 point
• 1-2 times = 2 points
• 3-4 times = 3 points
• 5-6 times = 4 points
• 7 or more times = 5 points

Total Score Interpretation:

• Mild: ≤6 points
• Moderate: 7-12 points
• Severe: 13-15 points

The PUQE score was developed and validated against the more complex Rhodes Index with excellent correlation (r=0.904, p<0.0001) 2, making it practical for both clinical use and research 3. It has been validated across multiple populations and languages 4 and predicts clinically important outcomes including emergency room visits, hospitalization rates, and patient well-being 5.

Clinical Context and Limitations

Important caveat: PUQE is valid for assessing mild to moderate nausea and vomiting in pregnancy (NVP) but is not valid for severe NVP and hyperemesis gravidarum (HG) 1. For severe cases requiring hospitalization, use the HELP (HyperEmesis Level Prediction) score instead to track treatment response 1.

Do not rely on ketonuria to assess severity—ketonuria is not associated with HG severity or dehydration in pregnancy 1. This is a common pitfall in clinical practice.

Severity-Based Management Algorithm

Mild NVP (PUQE ≤6)

First-line pharmacologic options 1:

• Doxylamine/Pyridoxine (vitamin B6): Start 20/20mg PO at bedtime; if inadequate, add 10/10mg in morning and 10/10mg at lunch
• Cyclizine: 50mg PO/IM/IV every 8 hours
• Prochlorperazine: 5-10mg PO every 6-8 hours (or 3mg buccal); 12.5mg IM/IV every 8 hours; 25mg PR daily
• Promethazine: 12.5-25mg PO/IM/IV every 4-8 hours
• Chlorpromazine: 10-25mg PO/IM/IV every 4-6 hours

Moderate NVP (PUQE 7-12)

Start with first-line agents as above. If symptoms persist or inadequate response, escalate to:

Second-line options 1:

• Metoclopramide: 5-10mg PO/IV/IM/SC every 8 hours
• Domperidone: 10mg PO every 8 hours; 30mg PR every 12 hours
• Ondansetron: 4mg every 8 hours or 8mg every 12 hours PO; 8mg IV over 15 minutes every 12 hours; 16mg PR daily
  • Prescribe laxatives prophylactically with ondansetron due to constipation risk

Severe NVP (PUQE 13-15)

Requires hospitalization for rehydration and VTE risk assessment 1. Use HELP score (not PUQE) to monitor treatment response 1.

Initiate second-line agents immediately. If standard therapies fail, consider:

Third-line option 1:

• Hydrocortisone: 100mg IV twice daily until clinical improvement, then convert to prednisolone 40-50mg PO daily, tapering by 5-10mg per week to lowest effective maintenance dose
  • Monitor blood pressure and screen for diabetes mellitus in all patients on corticosteroids
  • Continue previously effective antiemetics alongside corticosteroids

Key Management Principles

Stepwise escalation: Start with first-line agents and escalate based on treatment response, not just initial PUQE score 1. Recent data shows that m-HALP score and other inflammatory indices correlate with severity and re-hospitalization risk 6, 7, but these are research tools, not yet standard clinical practice.

Treatment timing matters: Studies show therapy is often delayed and inconsistent despite high NVP prevalence 8. Initiate pharmacologic treatment early for moderate symptoms (PUQE 7-12) rather than waiting for deterioration.

Risk stratification: Women with prior NVP history have 3-fold increased recurrence risk (OR 3.20,95% CI 2.12-4.83) 8—consider earlier intervention in this population.

Reassess regularly: PUQE correlates with treatment response over time 2, making it useful for monitoring therapeutic effectiveness at follow-up visits.